CTOs on the Move

Flame Biosciences

www.flame.bio

 
Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.flame.bio
  • 280 Union Square Drive
    New Hope, PA USA 18938
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Flame Biosciences raised $100M on 09/30/2020

Similar Companies

Cytiva

We`re the Life Sciences newcomer you already know. Cytiva is bringing our long-standing expertise to the forefront of science, to fuel research, discovery, and development with technologies, instruments, and software. We drive customer-centered innovation in 11 facilities across Asia, Europe and America from idea to commercial development stages.

Carolus Therapeutics

Carolus Therapeutics is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SelectX Pharmaceuticals

SelectX Pharmaceuticals, Inc. is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kali-Extracts

Making lives better with natural botanical therapies derived from our patented extraction process

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.